Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
Tanger Factory Outlet Centers, Inc. announced today that in honor of the 25th annual Tanger PINK Campaign it will again offer shoppers great savings in return for supporting the ongoing efforts to end breast cancer during the month of October.
Launching today at Tanger Outlets across the United States and Canada, the Tanger PINK Campaign offers shoppers using the Shop Pink Card the opportunity to receive additional savings on the best brand name and designer fashions while helping to unite in the fight against breast cancer.
To view the multimedia release go to:
https://www.multivu.com/players/English/8385651-tanger-outlets-tanger-pink-campaign-against-breast-cancer/
Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill’s recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. The initiative aims to encourage people 50 and older to talk with their healthcare provider about screening, including the modern, noninvasive options that can fit into any schedule of this busy, on-the-go “new 50” generation.
To view the multimedia release go to:
https://www.multivu.com/players/English/8280451-harry-and-jill-connick-colon-cancer-screening-the-new-50/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
In recognition of Metastatic Breast Cancer Awareness Day on October 13, AstraZeneca (NYSE: AZN) is raising awareness about the thousands of U.S. women living with metastatic breast cancer. Metastatic Breast Cancer Awareness Day seeks to generate attention and greater support for women living with metastatic breast cancer among the public and stakeholders within the breast cancer community and more research to extend lives.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58129-mbc-awareness
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
Today, WebMD released Advanced Breast Cancer: Courage, Comfort and Care with Robin Roberts, a five-part video series developed in partnership with Roberts and her independent production company, Rock’n Robin Productions. The series dives into the daily coping strategies of women living with advanced breast cancer, plus the families and friends who provide encouragement and support, and includes insights from medical experts leading the charge to combat the disease.
Over 255,000 people in the United States will be diagnosed with invasive breast cancer this year, and over 41,000 will die, with metastatic breast cancer being the leading cause of those fatalities. Despite these staggering statistics, there are signs of hope. Treatments for metastatic breast cancer are improving, and they continue to help people with the disease live longer and healthier lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8154851-webmd-advanced-breast-cancer-robin-roberts/
nanobébé, a brand dedicated to revolutionizing the infant feeding industry, today announced the launch of its much-anticipated sleek and modern ecosystem of health-focused feeding essentials for today’s 21st century parents, poised to be hot baby registry items this year. Breastfeeding moms can rejoice in the company’s flagship Breastmilk Bottle, the first and only baby bottle designed specifically to preserve essential breast milk nutrients. From pumping, storing, warming to feeding, the award-winning nanobébé Breastmilk Bottle protects the breast milk and preserves its nutritional value.
“When moms warm breast milk in the traditional way, there is a good chance that they are unknowingly damaging the nutritional and immunity-boosting properties of the milk. Additionally, the milk is likely heated unevenly, causing hot spots, which can harm the baby,” said Rallie McAllister, MD, MPH, nanobébé SpokesDoctor, family physician and coauthor of The Mommy MD Guide to Your Baby’s First Year. “nanobébé’s bottles are biomedically engineered with a concave shape that spreads the breast milk into a thin layer and allows it to warm at safe temperatures, protecting nutrients from damage and preventing hot spots.” The nanobébé Breastmilk Bottle warms stored breast milk quickly, twice as fast as standard bottles.
To view the multimedia release go to:
https://www.multivu.com/players/English/8260351-nanobebe-infant-breastfeeding-line/
More than 173,000 women in the United States are living with metastatic breast cancer and each has a story to tell. AstraZeneca is launching a nationwide photo-sharing campaign to provide them another way to share their inspiration, experiences and strengths with others.
To show their support, women living with metastatic breast cancer can upload photos of themselves on social media using the campaign hashtag #MBCStrength. Photos posted on Twitter by October 1, 2014 and tagged with #MBCStrength will be considered for a Times Square display in New York City on the fifth anniversary of Metastatic Breast Cancer Awareness Day on October 13, 2014.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7305551-mymbcstory-astrazeneca-encourages-women-with-metastatic-breast-cancer-to-share/
Susan G. Komen Knoxville readies the finish line for the 2014 Race for the Cure on October 18th at World’s Fair Park.
This year’s “Do You Tutu?” theme will attract a variety of pink tutus to the race. Komen Knoxville launched this theme to bring a sense of hope and happiness to the families, supporters and survivors battling breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7313552-komen-knoxville-laces-up-for-2014-race-for-the-cure-do-you-tutu/
